FMP
Odonate Therapeutics, Inc.
ODT
NASDAQ
Inactive Equity
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
1.12 USD
-0.04999995 (-4.46%)
About
ceo
Mr. Kevin Tang
sector
Healthcare
industry
Biotechnology
website
https://www.odonate.com
exchange
NASDAQ
Description
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
CIK
0001717452
ISIN
N/A
CUSIP
N/A
Address
4747 Executive Dr Ste 510
Phone
18582003830
Country
US
Employee
137
IPO Date
Dec 7, 2017
Summary
CIK
0001717452
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
-
ISIN
-
Country
US
Price
1.12
Beta
0.45
Volume Avg.
959.82k
Market Cap
0
Shares
-
52-Week
1.1107-1.2
DCF
5.77
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.41
P/B
-
Website
https://www.odonate.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ODT News
It looks like there's no news available.
